Intensive blood pressure lowering and the risk of new-onset diabetes in patients with hypertension: a post-hoc analysis of the STEP randomized trial
Primary resultResult — go to the resultAdjusted hazard ratio 1.01 95% CI 0.86–1.20Authors' conclusion
Intensive SBP lowering is not associated with an altered risk of new-onset diabetes or impaired fasting glucose in hypertensive patients.
Study context
- Population
- Elderly hypertensive patients in STEP with baseline fasting serum glucose (FSG) <7.0 mmol/L and no history of DM or hypoglycaemic medication use
- Participants
- 5,601 patients
- Comparison
- Intensive vs standard systolic blood pressure (SBP) control
- Primary endpoint
- New-onset DM (time to first FSG ≥7.0 mmol/L)
- Follow-up
- Median 3.42 years
Methodological detailspost-hoc analysis
- Post-hoc analysis
Primary result
As reported in the abstract
Adjusted hazard ratio
1.01
95% CI 0.86–1.20
Events by treatment group
Intensive vs Standard
adjusted HR 1.01 (95% CI 0.86–1.20)
Secondary outcomes
Mean highest FSG concentration during follow-up
New-onset impaired fasting glucose (FSG 5.6-6.9 mmol/L) in participants with normoglycemia · median follow-up 3.42 years
- Adjusted HR for the secondary outcome
- 1.04 (95% CI, 0.91-1.18)
Original publication
Intensive blood pressure lowering and the risk of new-onset diabetes in patients with hypertension: a post-hoc analysis of the STEP randomized trial. Eur J Prev Cardiol. Published 10 April 2023. doi:10.
Summarised from the published abstract; every number is checked against it